Evolus, Inc. EOLS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-8.65
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $297.2M | -$51.6M | $197.1M | -$45.7M | -$23.1M |
| 2024 | $266.3M | -$50.4M | $182.3M | -$19.5M | $5.5M |
| 2023 | $202.1M | -$61.7M | $137.6M | -$34.5M | -$20.7M |
| 2022 | $148.6M | -$74.4M | $89.8M | -$86.5M | $18.5M |
| 2021 | $99.7M | -$46.8M | — | -$33.8M | $81.9M |
| 2020 | $56.5M | -$163.0M | — | -$58.7M | -$73.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| MOATAZEDI DAVID | See Remarks | 2026-03-20 | Sell | 13,669 | $4.75 |
| Avelar Rui | See Remarks | 2026-03-20 | Sell | 3,119 | $4.75 |
| MOATAZEDI DAVID | See Remarks | 2026-03-17 | Sell | 116,720 | $4.89 |
| Avelar Rui | See Remarks | 2026-03-17 | Sell | 29,996 | $4.89 |
| MOATAZEDI DAVID | See Remarks | 2026-03-16 | Option exercise | 67,489 | — |
| Avelar Rui | See Remarks | 2026-03-16 | Option exercise | 8,804 | — |
| Malik Vikram | director | 2026-02-17 | Grant | 45,559 | — |
| Parschauer Karah Herdman | director | 2026-02-17 | Grant | 45,559 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -8.65 (distress)
- Working capital / assets 0.299
- Retained earnings / assets -2.927
- EBIT / assets -0.145
- Equity / liabilities -0.093
Source: SEC EDGAR filings · CIK 0001570562 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.